Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An oncolytic virus that kills cancer cells and triggers immune responses against tumors shows promise for children with brain cancer.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
75% of people treated with a combination of immunotherapy, targeted therapy and chemotherapy saw their tumors shrink.
Tumor-infiltrating lymphocytes are T cells that know how to recognize and fight cancer.
New checkpoint inhibitor Jemperli is approved for cancers with deficient mismatch repair mechanism for fixing damaged DNA.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
After a median follow-up of 13 months, four of the five patients had ongoing complete remission.
More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.
The Nobel Prize winner continues to search for more immune checkpoints that can be blocked.
However, a majority of these chronic immune-related side effects were mild.
Study participants who received Libtayo had a 31% lower risk of death than those treated with chemotherapy.
An inside look at five research developments that have the potential to transform the treatment of cancer
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
The theme of this issue is the science underlying advances in cancer care and treatment.
Opdivo plus Cabometyx reduced the risk of death by 40%.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.